VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
5362
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
858
Interactions with Platform & by Email
PARTICIPANTS
161
Unique # Participated
VALIDATIONS
72
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
123
PAGES
187
EDITION
16
PRICE
USD $5450
With the Global Economy Walking the Tightrope, It's the Numbers that Help Understand this Uncertain World.
Amid the COVID-19 crisis, the global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$777.8 Thousand in the year 2020, is projected to reach a revised size of US$1.8 Million by 2027, growing at a CAGR of 12.9% over the analysis period 2020-2027. Cytarabine, one of the segments analyzed in the report, is projected to record a 16.7% CAGR and reach US$698.7 Thousand by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anthracycline Drugs segment is readjusted to a revised 14% CAGR for the next 7-year period.
The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$209.4 Thousand in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$421.6 Thousand by the year 2027 trailing a CAGR of 17.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.
In the global Tyrosine Kinase Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$79.6 Thousand in the year 2020 will reach a projected size of US$145.7 Thousand by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$269 Thousand by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period. We bring years of research experience to this 16th edition of our report. The 187-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; Astellas Pharma Inc.; Astex Pharmaceuticals, Inc.; Celgene Corporation; CTI BioPharma Corp.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo Company Limited; F. Hoffmann-La Roche AG; Immune Pharmaceuticals Inc.; Janssen-Cilag Limited; Jazz Pharmaceuticals plc; MEI Pharma, Inc.; Novartis AG; Pfizer Inc.; Seattle Genetics, Inc.; Stemline Therapeutics, Inc.; Sunesis Pharmaceuticals, Inc.; Tolero Pharmaceuticals, Inc.
» Chemotherapy Type (Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, Other Chemotherapy Types)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlassâ„¢ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| A Prelude |
| Recent Market Activity |
| Growing Incidence and Poor Prognosis - A Fatal Concoction Creating Significant Unmet Needs |
| Inadequacies Marr Existing Therapeutics; Pipeline Therapies Offer Hope |
| Current and Future Analysis |
| Standard Mode of Treatment for AML - An Overview |
| Standard Approved Mode of Therapy for AML by Age Group |
| List of FDA-Approved Chemotherapy Drugs for Treatment of AML |
| Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics |
| Global Competitor Market Shares |
| Acute Myeloid Leukemia (AML) Therapeutics Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| AbbVie Inc. (USA) |
| Actinium Pharmaceuticals, Inc. (USA) |
| Agios Pharmaceuticals, Inc. (USA) |
| Amgen Inc. (USA) |
| Astellas Pharma Inc. (Japan) |
| Astex Pharmaceuticals, Inc. (USA) |
| Celgene Corporation (USA) |
| CTI BioPharma Corp. (USA) |
| Cyclacel Pharmaceuticals, Inc. (USA) |
| Daiichi Sankyo Company Limited (Japan) |
| F. Hoffmann-La Roche AG (Switzerland) |
| Immune Pharmaceuticals Inc. (USA) |
| Janssen-Cilag Limited (UK) |
| Jazz Pharmaceuticals plc (Ireland) |
| MEI Pharma, Inc. (USA) |
| Merus N.V. (The Netherlands) |
| Novartis AG (Switzerland) |
| Pfizer Inc. (USA) |
| Seattle Genetics, Inc. (USA) |
| Stemline Therapeutics, Inc. (USA) |
| Sunesis Pharmaceuticals, Inc. (USA) |
| Tolero Pharmaceuticals, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Growing Interest in the Genetics of AML |
| Targeted Therapies Hog Limelight in AML Therapeutic Pipeline |
| Select Major AML Therapeutics in Late-Stage Clinical Development |
| Select AML Therapeutics in Phase I and II Clinical Development |
| FLT3 - The Most Advanced Natural Target |
| Chemotherapy Retains Developers’ Interest; Better Chemotherapies on the Horizon |
| Vyxeos - The New Standard of Care in AML Treatment? |
| Select Benefits of Vyxeos in a Gist: |
| Drug Targeting Mutant IDH2 Enzyme Enters Pivotal Trials |
| Immunotherapies in Development too Show Promise |
| Annamycin Shows Promise as a Second Line Therapy for AML |
| Volasertib - the First in Molecular Targeting Agents for AML to Advance in Clinical Trials |
| ADCs’ Clinical Trials Depict Mixed Results |
| Research Innovations/Findings in AML Therapeutics |
| Anti-CD98 Antibodies Offer Novel Approach |
| Inhibition of Metabolic Enzyme in AML Pathway Identified as an Promising Option |
| Personalized Vaccine Approach Invades AML Therapeutic R&D |
| Ceramide-based Therapeutic Targets Drug Resistance of AML |
| Fructose - Potential Target for AML Therapeutics |
| 4. GLOBAL MARKET PERSPECTIVE |
| Acute Myeloid Leukemia (AML) Therapeutics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Cytarabine (Chemotherapy Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Cytarabine (Chemotherapy Type) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Cytarabine (Chemotherapy Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Anthracycline Drugs (Chemotherapy Type) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| Anthracycline Drugs (Chemotherapy Type) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 |
| Anthracycline Drugs (Chemotherapy Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Tyrosine Kinase Inhibitors (Chemotherapy Type) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 |
| Tyrosine Kinase Inhibitors (Chemotherapy Type) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017 |
| Tyrosine Kinase Inhibitors (Chemotherapy Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Alkylating Agents (Chemotherapy Type) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 |
| Alkylating Agents (Chemotherapy Type) Market Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Alkylating Agents (Chemotherapy Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Hormonal Therapy (Chemotherapy Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Hormonal Therapy (Chemotherapy Type) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Hormonal Therapy (Chemotherapy Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Anti-Metabolites (Chemotherapy Type) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018 to 2025 |
| Anti-Metabolites (Chemotherapy Type) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Anti-Metabolites (Chemotherapy Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 |
| Other Chemotherapy Types (Chemotherapy Type) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2018 to 2025 |
| Other Chemotherapy Types (Chemotherapy Type) Global Historic Demand in US$ Thousand by Region/Country: 2009 to 2017 |
| Other Chemotherapy Types (Chemotherapy Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Acute Myeloid Leukemia (AML) Therapeutics Market Share (in %) by Company: 2020 & 2025 |
| United States Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Projections in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in the United States by Chemotherapy Type: A Historic Review in US$ Thousand for 2009-2017 |
| United States Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Canada |
| Canadian Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Canadian Acute Myeloid Leukemia (AML) Therapeutics Historic Market Review by Chemotherapy Type in US$ Thousand: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Chemotherapy Type for 2009, 2019, and 2025 |
| Japan |
| Japanese Market for Acute Myeloid Leukemia (AML) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Japan: Historic Sales Analysis in US$ Thousand by Chemotherapy Type for the Period 2009-2017 |
| Japanese Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| China |
| Chinese Acute Myeloid Leukemia (AML) Therapeutics Market Growth Prospects in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in China in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Chinese Acute Myeloid Leukemia (AML) Therapeutics Market by Chemotherapy Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Europe |
| Market Facts & Figures |
| European Acute Myeloid Leukemia (AML) Therapeutics Market: Competitor Market Share Scenario (in %) for 2020 & 2025 |
| European Acute Myeloid Leukemia (AML) Therapeutics Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 |
| European Acute Myeloid Leukemia (AML) Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Europe in US$ Thousand by Chemotherapy Type: A Historic Review for the Period 2009-2017 |
| European Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| France |
| Acute Myeloid Leukemia (AML) Therapeutics Market in France by Chemotherapy Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Acute Myeloid Leukemia (AML) Therapeutics Historic Market Scenario in US$ Thousand by Chemotherapy Type: 2009-2017 |
| French Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Germany |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| German Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in US$ Thousand by Chemotherapy Type: 2009-2017 |
| German Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Italy |
| Italian Acute Myeloid Leukemia (AML) Therapeutics Market Growth Prospects in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in Italy in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Italian Acute Myeloid Leukemia (AML) Therapeutics Market by Chemotherapy Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Kingdom |
| United Kingdom Market for Acute Myeloid Leukemia (AML) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Chemotherapy Type for the Period 2009-2017 |
| United Kingdom Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Spain |
| Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Spanish Acute Myeloid Leukemia (AML) Therapeutics Historic Market Review by Chemotherapy Type in US$ Thousand: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Chemotherapy Type for 2009, 2019, and 2025 |
| Russia |
| Russian Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Projections in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Russia by Chemotherapy Type: A Historic Review in US$ Thousand for 2009-2017 |
| Russian Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Rest of Europe in US$ Thousand by Chemotherapy Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Asia-Pacific |
| Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 |
| Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Asia-Pacific by Chemotherapy Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Historic Market Scenario in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Australia |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Australian Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Australian Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| India |
| Indian Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Indian Acute Myeloid Leukemia (AML) Therapeutics Historic Market Review by Chemotherapy Type in US$ Thousand: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in India: Percentage Share Breakdown of Sales by Chemotherapy Type for 2009, 2019, and 2025 |
| South Korea |
| Acute Myeloid Leukemia (AML) Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| South Korean Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market Share Distribution in South Korea by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Rest of Asia-Pacific |
| Rest of Asia-Pacific Market for Acute Myeloid Leukemia (AML) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Chemotherapy Type for the Period 2009-2017 |
| Rest of Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Latin America |
| Latin American Acute Myeloid Leukemia (AML) Therapeutics Market Trends by Region/Country in US$ Thousand: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 |
| Latin American Acute Myeloid Leukemia (AML) Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 |
| Latin American Acute Myeloid Leukemia (AML) Therapeutics Market Growth Prospects in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in Latin America in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Latin American Acute Myeloid Leukemia (AML) Therapeutics Market by Chemotherapy Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Argentina |
| Argentinean Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Argentina in US$ Thousand by Chemotherapy Type: A Historic Review for the Period 2009-2017 |
| Argentinean Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Brazil |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Brazil by Chemotherapy Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Brazilian Acute Myeloid Leukemia (AML) Therapeutics Historic Market Scenario in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Brazilian Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Mexico |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Mexican Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Mexican Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Rest of Latin America |
| Rest of Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Projections in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Rest of Latin America by Chemotherapy Type: A Historic Review in US$ Thousand for 2009-2017 |
| Rest of Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Middle East |
| The Middle East Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 |
| The Middle East Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025 |
| The Middle East Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| The Middle East Acute Myeloid Leukemia (AML) Therapeutics Historic Market by Chemotherapy Type in US$ Thousand: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Chemotherapy Type for 2009, 2019, and 2025 |
| Iran |
| Iranian Market for Acute Myeloid Leukemia (AML) Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Iran: Historic Sales Analysis in US$ Thousand by Chemotherapy Type for the Period 2009-2017 |
| Iranian Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Israel |
| Israeli Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Forecasts in US$ Thousand by Chemotherapy Type: 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Israel in US$ Thousand by Chemotherapy Type: A Historic Review for the Period 2009-2017 |
| Israeli Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Saudi Arabia |
| Saudi Arabian Acute Myeloid Leukemia (AML) Therapeutics Market Growth Prospects in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in Saudi Arabia in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Saudi Arabian Acute Myeloid Leukemia (AML) Therapeutics Market by Chemotherapy Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Arab Emirates |
| Acute Myeloid Leukemia (AML) Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| United Arab Emirates Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Acute Myeloid Leukemia (AML) Therapeutics Market Share Distribution in United Arab Emirates by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Rest of Middle East |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Chemotherapy Type for the Period 2018-2025 |
| Rest of Middle East Acute Myeloid Leukemia (AML) Therapeutics Historic Market Analysis in US$ Thousand by Chemotherapy Type: 2009-2017 |
| Rest of Middle East Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| Africa |
| African Acute Myeloid Leukemia (AML) Therapeutics Market Estimates and Projections in US$ Thousand by Chemotherapy Type: 2018 to 2025 |
| Acute Myeloid Leukemia (AML) Therapeutics Market in Africa by Chemotherapy Type: A Historic Review in US$ Thousand for 2009-2017 |
| African Acute Myeloid Leukemia (AML) Therapeutics Market Share Breakdown by Chemotherapy Type: 2009 VS 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 68 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com